Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Market Cap	10.95B -13.2%
Revenue (ttm)	2.74B -8.2%
Net Income	419.90M -10.7%
EPS	1.81 -37.8%
Shares Out	226.13M
PE Ratio	14.49
Forward PE	n/a
Dividend	1.13 (4.23%)
Ex-Dividend Date	Sep 5, 2025

Volume	139,600
Average Volume	181,927
Open	26.02
Previous Close	26.18
Day's Range	25.86 - 26.78
52-Week Range	21.70 - 34.35
Beta	0.54
RSI	51.25
Earnings Date	Mar 21, 2026

About HKG:6826

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyaluronate gel, anti-adhesion, and burn wound related products. In addition, it provides injectors, scalpels, suture needles and other products. Further, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 2,156
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6826

Financial Performance

In 2024, HKG:6826's revenue was 2.68 billion, an increase of 1.70% compared to the previous year's 2.63 billion. Earnings were 420.45 million, an increase of 1.04%.

Financial numbers in CNY